FMR1 and fragile X syndrome: These findings provide proof-of-concept for a CRISPR based approach to gene reactivation in FXS patient cells with the potential for translation to in vivo systems, but with the caveat that large transcribed CGG repeats may introduce an additional blockade on FMRP translation.